AstraZeneca rare disease drug misses primary goal in late-stage trial

• Ultomiris missed statistical significance for event-free survival at 26 weeks in adult patients with stem cell transplant-associated thrombotic microangiopathy, though showed a positive trend
• A pediatric trial showed more promise with 87.2% overall survival at 26 weeks and 73.4% at 52 weeks, prompting AstraZeneca to advance regulatory filings for children
• The setback follows recent failures including a rejected breast cancer drug in May and comes as AstraZeneca targets $80 billion in annual revenue by 2030 through up to 20 new drug launches

AstraZeneca Rare Disease Drug Fails Late-Stage Trial

AstraZeneca announced Monday that its rare disease drug Ultomiris failed to meet its primary endpoint in a late-stage trial for patients with haematopoietic stem cell transplant-associated thrombotic microangiopathy, marking another setback for the drugmaker's pipeline this year.

Key Trial Results:

• Ultomiris did not achieve statistical significance for event-free survival at 26 weeks in adult patients, though it showed a trend toward benefit
• In a separate pediatric trial, the drug demonstrated an 87.2% overall survival rate at 26 weeks and 73.4% at 52 weeks
• AstraZeneca will proceed with regulatory filings for pediatric use and is discussing next steps with global health authorities for the adult indication

Context of Recent Setbacks:

This failure follows a string of disappointments in 2024, including safety concerns raised earlier this month and the May rejection of breast cancer drug camizestrant by a U.S. regulatory panel. These setbacks have raised concerns about AstraZeneca's drug development pipeline.

Positive Development:

The company reported that experimental gastric cancer drug sonesitatug vedotin met its key goal, showing statistically significant and clinically meaningful improvement in overall survival for advanced gastric cancer patients.

Market Implications:

AstraZeneca is targeting $80 billion in annual revenue by 2030, relying on up to 20 new drug launches driven by cancer and rare disease therapies. The recent trial failures could impact investor confidence in achieving these ambitious targets.

Ultomiris (ravulizumab) is currently approved in the U.S., EU, and Japan for treating certain rare blood disorders and neurological conditions.